About Copaiba Oleoresin Extract
Copaiba oleoresin contains beta-caryophyllene, a CB2 receptor agonist with anti-inflammatory activity in animal models. However, clinical evidence is extremely limited — a scientometric review found only 2.59% of studies are clinical trials, and those used topical application, not oral supplementation. No oral RCTs exist with dose-defined beta-caryophyllene. Preclinical promise but insufficient human evidence to support clinical claims.
What Copaiba Oleoresin Extract supports
- Contains beta-caryophyllene (CB2 agonist) with anti-inflammatory activity in preclinical studies — no oral human RCTs
How much Copaiba Oleoresin Extract to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
500–2000
mg
No established clinical dose from RCTs. Typical supplement doses are 500–2000 mg copaiba oil. Only 2 human trials exist (topical use only). Most evidence is preclinical.
Clinical evidence
Limited clinical evidence. No oral human clinical trials exist; only preclinical studies and 2 topical-use human studies
Examine.com